Koers Cannex Capital Holdings Inc Canadian Securities Exchange
Aandelen
CA13768L1085
Farmaceutische producten
Omzet 2024 * | 88,7 mln. 121 mln. 81,73 mln. | Omzet 2025 * | - | Marktkapitalisatie | 93,89 mln. 128 mln. 86,51 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 1,06 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 0% |
Recentste transcriptie over Cannex Capital Holdings Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 38 | - | |
Andrew Thut
CEO | Chief Executive Officer | 50 | 01-10-14 |
Karl Chowscano
PSD | President | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rob Hunt
CHM | Chairman | 51 | 12-04-22 |
Anthony Dutton
PRN | Corporate Officer/Principal | 66 | - |
Chetan Gulati
BRD | Director/Board Member | 46 | 01-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+43,31% | 6,29 mld. | |
-16,99% | 4,42 mld. | |
+6,39% | 3,3 mld. | |
-13,10% | 3,05 mld. | |
-4,17% | 2,47 mld. | |
+45,47% | 1,94 mld. | |
-9,11% | 1,66 mld. | |
-2,09% | 1,61 mld. | |
-12,50% | 1,54 mld. |